{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-005077","form_type":"8-K","ticker":"RGNX","cik":"0001590877","company_name":"REGENXBIO Inc.","filed_at":"2023-02-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.735292+00:00","generated_at":"2026-06-18T22:10:12.803908+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"REGENXBIO Q4 net loss $59.9M ($1.38/share); revenue $31.3M vs $398.7M YoY; cash $565M","bullets":["Full-year 2022 net loss $280.3M ($6.50/share) vs net income $127.8M in 2021.","Revenue fell to $112.7M in 2022 from $470.3M, driven by $370M non-recurring AbbVie collaboration revenue in 2021.","Zolgensma royalties rose to $101.9M in 2022 from $95.0M in 2021.","Cash, equivalents and marketable securities $565.2M as of Dec 31, 2022, down from $849.3M; runway into 2025.","RGX-314 pivotal trials ongoing with BLA expected in 2024; RGX-121 pivotal enrollment to complete H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-005077","json":"https://secwatch.observer/filing/0000950170-23-005077.json","markdown":"https://secwatch.observer/filing/0000950170-23-005077.md","text":"https://secwatch.observer/filing/0000950170-23-005077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/0000950170-23-005077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/rgnx-20230228.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T22:10:12.803908+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f55fcec5a2396b2dbabb9e6749b3b1a3e4a13d21","claim":"REGENXBIO Inc. reported financial results for the quarter and year ended December 31, 2022.","evidence_excerpt":"On February 28, 2023, REGENXBIO Inc. (the “Company”) issued a press release regarding its results of operations and financial condition for the quarter and year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1590877/000095017023005077/0000950170-23-005077-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter and year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}